Too Few Visible Catalysts For Revance Push Guggenheim to The Sidelines
January 09, 2018 at 17:44 PM EST
Revance Therapeutics Inc (NASDAQ: RVNC) announced interim Phase 2a results for RT002 in treating Plantar Fasciitis, which showed ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|